|Awarded On||November 19, 2014|
|Title||Oral Stat3 Inhibitor as Targeted Treatment for Triple-Negative Breast Cancer|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||David J Tweardy|
An estimated 230,480 new cases of invasive breast cancer will be diagnosed in the US in 2014. Of these, ~40,000 will suffer breast cancer relapse. The breast cancers in half of those that relapse will lack the three breast cancer markers that help guide therapy and are referred to as triple-negative breast cancer (TNBC). There currently are no effective treatments for patients with TNBC.
We and other groups have demonstrated that TNBC tumors contain small numbers of cancer cells that persist after standard chemotherapy and cause tumor relapse. We showed that these persisting cancer cells express a new tumor marker, termed Stat3 that is essential for their survival and growth. These findings ...